Looming questions for Japan pharma

11 October 2018
japan-mount-fuji-large-1-

For a very long time executives visiting or living in Japan agonized over what they perceived as resistance to change and a drawn out, time consuming decision-making process, writes long-time Japan pharma watcher and president of International Alliances Limited P Reed Maurer in his exclusive column for The Pharma Letter.

Yes, a bottom up, consensus management style takes more time than a top down, command process. What is often missed is the rapid, effective execution of decisions. One example is the evolution of the distribution sector.

When I arrived in Japan in 1970 there were 1,500 pharmaceutical wholesalers. Each one had limited local coverage of hospitals and drug stores. Today there are basically four wholesalers, each with national coverage. This consolidation resulted in only one wholesaler going bankrupt and closing shop. All others merged through friendly agreements. There were no hostile take overs.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical